X4 PHARMACEUTICALS, INC (XFOR) Debt Components
- 2026-06-30: Long-term DebtUSD $75.00M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m); Long-Term Debt, Maturity, Year ThreeUSD (m).
- 2026-03-31: Long-term DebtUSD $75.00M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m); Long-Term Debt, Maturity, Year ThreeUSD (m).
- 2025-12-31: Long-term DebtUSD $75.00M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m); Long-Term Debt, Maturity, Year ThreeUSD (m).
- 2025-12-31: Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD $0.00; Long-Term Debt, Maturity, Year TwoUSD $76.70M; Long-Term Debt, Maturity, Year ThreeUSD (m).
X4 PHARMACEUTICALS, INC Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Debt Instrument, Unamortized Discount (Premium), Net USD | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt and Lease Obligation, Including Current Maturities USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-term Debt, Gross USD | Debt Instrument, Periodic Payment, Principal USD | Debt Instrument, Unamortized Discount, Current USD | Debt Instrument, Unamortized Discount, Noncurrent USD | Debt Instrument, Unamortized Discount USD | Debt Instrument, Unamortized Premium USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $75.00M | (m) | (m) | (m) | (m) | $283.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $75.00M | (m) | (m) | (m) | (m) | $349.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $75.00M | (m) | (m) | (m) | (m) | $412.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $0.00 | $76.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $75.00M | $0.00 | $76.54M | (m) | $0.00 | $475.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $75.00M | $0.00 | $76.38M | (m) | $0.00 | $536.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $75.00M | $0.00 | $76.22M | (m) | $0.00 | $594.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $75.00M | (m) | (m) | (m) | (m) | $650.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $0.00 | $0.00 | $76.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $75.00M | $0.00 | $0.00 | (m) | $0.00 | $706.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $75.00M | $0.00 | $0.00 | (m) | $0.00 | $759.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $55.00M | $24.72M | $30.93M | (m) | $0.00 | $825.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $55.00M | (m) | (m) | (m) | (m) | $917.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $2.10M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $0.00 | $24.72M | $30.77M | (m) | (m) | $0.00 | $54.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $2.10M | (m) | (m) | (m) | (m) |
| 2023-09-30 | $55.00M | (m) | (m) | (m) | (m) | $1.01M | $0.00 | (m) | $54.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-08-02 | (m) | (m) | (m) | $75.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-08-02 | (m) | $0.00 | $24.72M | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $1.30M | (m) | (m) | (m) | (m) |
| 2023-06-30 | $32.50M | $4.74M | $20.38M | $7.57M | $764.00K | $858.00K | $764.00K | (m) | $31.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $1.30M | (m) | (m) | (m) | (m) |
| 2023-03-31 | $32.50M | $4.75M | $20.39M | $7.46M | $554.00K | $767.00K | $554.00K | (m) | $31.83M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $800.00K | (m) | (m) | (m) | (m) |
| 2022-12-31 | $32.50M | (m) | (m) | (m) | (m) | $196.00K | $1.31M | $32.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $32.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $14.04M | $19.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $800.00K | (m) | (m) | (m) | (m) |
| 2022-09-30 | $32.50M | $20.05M | $13.53M | (m) | $0.00 | $221.00K | $14.62M | (m) | $18.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $800.00K | (m) | (m) | (m) | (m) |
| 2022-06-30 | $32.50M | $19.97M | $13.36M | (m) | $0.00 | $238.00K | $8.61M | (m) | $24.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $800.00K | (m) | (m) | (m) | (m) |
| 2022-03-31 | $32.50M | $19.80M | $13.29M | (m) | $0.00 | $-127.00K | $3.42M | (m) | $29.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $32.50M | (m) | (m) | (m) | (m) | $-277.00K | $795.00K | $33.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $33.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $21.47M | $11.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $32.50M | $0.00 | $21.18M | $11.31M | $0.00 | $-266.00K | $693.00K | (m) | $33.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $32.50M | $0.00 | $21.18M | $11.31M | $0.00 | $-253.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $32.50M | $0.00 | $21.18M | $11.31M | $0.00 | $-237.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $32.50M | (m) | (m) | (m) | (m) | $-223.00K | $0.00 | $33.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $33.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $0.00 | $21.18M | (m) | (m) | (m) | (m) | (m) | $11.31M | (m) | (m) | (m) | (m) | (m) | (m) | $223.00K |
| 2020-09-30 | $25.00M | $0.00 | $14.87M | $10.13M | $0.00 | $-229.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $25.00M | (m) | $0.00 | $14.87M | $0.00 | $-234.00K | (m) | (m) | (m) | $10.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $25.00M | (m) | $0.00 | $14.87M | $0.00 | $-238.00K | (m) | (m) | (m) | $10.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $20.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $317.00K | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $317.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $0.00 | $11.90M | $0.00 | (m) | $0.00 | $20.00M | (m) | $8.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $20.00M | (m) | $0.00 | $0.00 | $0.00 | (m) | $0.00 | $20.00M | (m) | $11.90M | $8.10M | (m) | (m) | (m) | (m) | $317.00K | (m) |
| 2019-06-30 | $26.72M | (m) | $4.52M | $2.20M | $0.00 | (m) | $4.15M | $22.20M | (m) | $11.90M | $8.10M | (m) | (m) | (m) | (m) | $672.00K | (m) |
| 2019-03-31 | $19.55M | (m) | $8.77M | $6.52M | $4.26M | (m) | $5.30M | $14.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.02M | (m) |
| 2018-12-31 | $10.00M | (m) | (m) | (m) | (m) | (m) | $1.69M | $8.31M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $226.00K | (m) |
| 2018-12-31 | (m) | (m) | $4.95M | $3.93M | (m) | (m) | (m) | (m) | (m) | $859.00K | (m) | $9.74M | (m) | (m) | $1.84M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $12.79M | (m) | $9.00K | $2.04M | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $13.44M | (m) | $14.00K | $2.23M | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $14.56M | (m) | $15.00K | $2.53M | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $14.89M | (m) | $19.00K | $2.64M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |